Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2020

01-12-2020 | Insulins

Current perspectives of oleic acid: Regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes

Authors: Kanwal Rehman, Kamran Haider, Komal Jabeen, Muhammad Sajid Hamid Akash

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2020

Login to get access

Abstract

Insulin resistance (IR) and type 2 diabetes mellitus (T2DM) is a leading cause of deaths due to metabolic disorders in recent years. Molecular mechanisms involved in the initiation and development of IR and T2DM are multiples. The major factors include mitochondrial dysfunction which may cause incomplete fatty acid oxidation (FAO). Oleic acid upregulates the expression of genes causing FAO by deacetylation of PGC1α by PKA-dependent activation of SIRT1-PGC1α complex. Another potent factor for the development of IR and T2DM is endothelial dysfunction as damaged endothelium causes increased release of inflammatory mediators such as TNF-α, IL-6, IL-1β, sVCAM, sICAM, E-selectin and other proinflammatory cytokines. While, on the other hand, oleic acid has the ability to regulate E-selectin, and sICAM expression. Rest of the risk factors may include inflammation, β-cell dysfunction, oxidative stress, hormonal imbalance, apoptosis, and enzyme dysregulation. Here, we have highlighted how oleic acid regulates underlying causatives factors and hence, keeps surpassing effect in prevention and treatment of IR and T2DM. However, the percentage contribution of these factors in combating IR and ultimately averting T2DM is still debatable. Thus, because of its exceptional protective effect, it can be considered as an improved therapeutic agent in prophylaxis and/or treatment of IR and T2DM.
Literature
1.
Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L, et al. Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective observational studies. BMJ. 2019;366:l2368.PubMedPubMedCentral
2.
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152–61.PubMed
3.
Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing type 2 diabetes: a narrative review of the evidence. Nutrients. 2019;11(4):766.PubMedCentral
4.
Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: fire from within. Int J Mol Sci. 2019;20(3):562.PubMedCentral
5.
Ekpenyon CE. Relationship between insulin resistance and metabolic syndrome clusters: current knowledge. Acta Sci Med Sci. 2019;3(3):99–104.
6.
Ingelfinger JR, Rosen CJ. Clinical credence - SGLT2 inhibitors, diabetes, and chronic kidney disease. N Engl J Med. 2019;380(24):2371–3.
7.
Arsic A, Stojanovic A, Mikic M. Oleic acid-health benefits and status in plasma phospholipids in the Serbian population. Serbian J Exp Clin Res. 2019;20(2):3–8.
8.
Bowen KJ, Kris-Etherton PM, West SG, Fleming JA, Connelly PW, Lamarche B, et al. Diets enriched with conventional or high-oleic acid canola oils lower Atherogenic lipids and lipoproteins compared to a diet with a Western fatty acid profile in adults with central adiposity. J Nutr. 2019;149(3):471–8.PubMedPubMedCentral
9.
Gonçalves-de-Albuquerque CF, Medeiros-de-Moraes IM, de Jesus Oliveira FM, Burth P, Bozza PT, Faria MVC, et al. Omega-9 oleic acid induces fatty acid oxidation and decreases organ dysfunction and mortality in experimental sepsis. PLoS One. 2016;11(4):e0153607.PubMedPubMedCentral
10.
Lim J-H, Gerhart-Hines Z, Dominy JE, Lee Y, Kim S, Tabata M, et al. Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1α complex. J Biol Chem. 2013;288(10):7117–26.PubMedPubMedCentral
11.
Naughton S, Hanson E, Mathai M, McAinch A. The acute effect of oleic-or linoleic acid-containing meals on appetite and metabolic markers; a pilot study in overweight or obese individuals. Nutrients. 2018;10(10):1376.PubMedCentral
12.
Nemecz M, Constantin A, Dumitrescu M, Alexandru N, Filippi A, Tanko G, et al. The distinct effects of Palmitic and oleic acid on pancreatic Beta cell function: the elucidation of associated mechanisms and effector molecules. Front Pharmacol. 2018;9:1554.PubMed
13.
Melo HM, Santos LE, Ferreira ST. Diet-derived fatty acids, brain inflammation, and mental health. Front Neurosci. 2019;13.
14.
Scoditti E, Massaro M, Carluccio MA, Pellegrino M, Wabitsch M, Calabriso N, et al. Additive regulation of adiponectin expression by the mediterranean diet olive oil components oleic acid and hydroxytyrosol in human adipocytes. PLoS One. 2015;10(6):e0128218.PubMedPubMedCentral
15.
Chen X, Stein TP, Steer RA, Scholl TO. Individual free fatty acids have unique associations with inflammatory biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic pregnant women. BMJ Open Diabetes Res Care. 2019;7(1):e000632.PubMedPubMedCentral
16.
Arab K, Rossary A, Soulere L, Steghens JP. Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006;96(5):811–9.PubMed
17.
Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Endocrinol Metab. 2019;316(2):E268–E85.PubMedPubMedCentral
18.
19.
Sergi D, Naumovski NN, Heilbronn LHK, Abeywardena M, O'Callaghan N, Lionetti L, et al. Mitochondrial (Dys) function and insulin resistance: from pathophysiological molecular mechanisms to the impact of diet. Front Physiol. 2019;10:532.PubMedPubMedCentral
20.
Coll T, Eyre E, Rodríguez-Calvo R, Palomer X, Sánchez RM, Merlos M, et al. Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. J Biol Chem. 2008;283(17):11107–16.PubMed
21.
Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813(7):1269–78.PubMed
22.
Hu W, Ross J, Geng T, Brice SE, Cowart LA. Differential regulation of dihydroceramide desaturase by palmitate versus monounsaturated fatty acids: implications for insulin resistance. J Biol Chem. 2011;286(19):16596–605.PubMedPubMedCentral
23.
Herrero L, Rubí B, Sebastián D, Serra D, Asins G, Maechler P, et al. Alteration of the malonyl-CoA/carnitine palmitoyltransferase I interaction in the β-cell impairs glucose-induced insulin secretion. Diabetes. 2005;54(2):462–71.PubMed
24.
Zang Y, Wang T, Xie W, Wang-Fischer YL, Getty L, Han J, et al. Regulation of acetyl CoA carboxylase and carnitine palmitoyl transferase-1 in rat adipocytes. Obes Res. 2005;13(9):1530–9.PubMed
25.
Priore P, Gnoni A, Natali F, Testini M, Gnoni GV, Siculella L, et al. Oleic acid and hydroxytyrosol inhibit cholesterol and fatty acid synthesis in C6 glioma cells. Oxidative Med Cell Longev. 2017;2017:9076052.
26.
Pierelli G, Stanzione R, Forte M, Migliarino S, Perelli M, Volpe M, et al. Uncoupling protein 2: a key player and a potential therapeutic target in vascular diseases. Oxidative Med Cell Longev. 2017;2017:7348372.
27.
Teshima Y, Akao M, Jones SP, Marbán E. Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res. 2003;93(3):192–200.PubMed
28.
Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol. 2005;6(3):248–61.PubMed
29.
Pi J, Collins S. Reactive oxygen species and uncoupling protein 2 in pancreatic beta-cell function. Diabetes Obes Metab. 2010;12(Suppl 2):141–8.PubMed
30.
Medvedev AV, Robidoux J, Bai X, Cao W, Floering LM, Daniel KW, et al. Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J Biol Chem. 2002;277(45):42639–44.PubMed
31.
Šrámek J, Němcová-Fürstová V, Pavlíková N, Kovář J. Effect of saturated stearic acid on MAP kinase and ER stress signaling pathways during apoptosis induction in human pancreatic β-cells is inhibited by unsaturated oleic acid. Int J Mol Sci. 2017;18(11):2313.PubMedCentral
32.
33.
Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283–307.PubMed
34.
Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp. 2013;61(2):119–25.
35.
36.
Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun HL. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Front Immunol. 2014;5:470.PubMedPubMedCentral
37.
Camell C, Smith CW. Dietary oleic acid increases m2 macrophages in the mesenteric adipose tissue. PLoS One. 2013;8(9):e75147.PubMedPubMedCentral
38.
Mandavia C, Sowers JR. Phosphoprotein phosphatase PP2A regulation of insulin receptor substrate 1 and insulin metabolic signaling. Cardiorenal Med. 2012;2(4):308–13.PubMedPubMedCentral
39.
Nardi F, Lipina C, Magill D, Hassan RH, Hajduch E, Gray A, et al. Enhanced insulin sensitivity associated with provision of mono and polyunsaturated fatty acids in skeletal muscle cells involves counter modulation of PP2A. PLoS One. 2014;9(3):e92255.PubMedPubMedCentral
40.
Li J, Song J, Li X, Rock SB, Sinner HF, Weiss HL, et al. FFAR4 is involved in regulation of neurotensin release from neuroendocrine cells and male C57BL/6 mice. Endocrinology. 2018;159(8):2939–52.PubMedPubMedCentral
41.
Houthuijzen JM. For better or worse: FFAR1 and FFAR4 signaling in cancer and diabetes. Mol Pharmacol. 2016;90(6):738–43.PubMed
42.
Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11(Suppl 4):10–20.PubMedPubMedCentral
43.
Morgan NG, Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochem Pharmacol. 2009;78(12):1419–27.PubMed
44.
Rogers K, Davis D, Kurjiaka D. Role of the free fatty acid 4 receptor in endothelial cell responses to oleic acid. FASEB J. 2017;31(1_supplement):lb763-lb.
45.
Bloemer J, Pinky PD, Govindarajulu M, Hong H, Judd R, Amin RH, et al. Role of adiponectin in central nervous system disorders. Neural Plast. 2018;2018.
46.
Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4(1):44–9.PubMed
47.
Patel S, Hoehn K, Lawrence R, Sawbridge L, Talbot N, Tomsig J, et al. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology. 2012;153(11):5231–46.PubMedPubMedCentral
48.
Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes. 2010;34(1):165–71.
49.
Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab. 2006;4(1):75–87.PubMedPubMedCentral
50.
Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology. 2009;49(4):1176–84.PubMed
51.
Janus A, Szahidewicz-Krupska E, Mazur G, Doroszko A. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediat Inflamm. 2016;2016:3634948.
52.
D'Oria R, Laviola L, Giorgino F, Unfer V, Bettocchi S, Scioscia M. PKB/Akt and MAPK/ERK phosphorylation is highly induced by inositols: novel potential insights in endothelial dysfunction in preeclampsia. Pregnancy Hypertens. 2017;10:107–12.PubMed
53.
Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–10.PubMed
54.
Medeiros-de-Moraes IM, Gonçalves-de-Albuquerque CF, Kurz AR, Oliveira FM, Abreu VHP, Torres RC, et al. Omega-9 oleic acid, the main compound of olive oil, mitigates inflammation during experimental sepsis. Oxidative Med Cell Longev. 2018;2018.
55.
Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol. 2004;44(1):44–9.PubMed
56.
Powell LA, Flood A, Jewhurst V, Owens D. Effects of oleic versus linoleic acids on adhesion molecule expression in glucose-treated vascular endothelial cells. Diabetes. 2005;54:A188.
57.
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.PubMedPubMedCentral
58.
Doi Y, Kiyohara Y, Kubo M, Tanizaki Y, Okubo K, Ninomiya T, et al. Relationship between C-reactive protein and glucose levels in community-dwelling subjects without diabetes: the Hisayama study. Diabetes Care. 2005;28(5):1211–3.PubMed
59.
Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010;6(1):27–34.PubMed
60.
Kusche-Vihrog K, Urbanova K, Blanqué A, Wilhelmi M, Schillers H, Kliche K, et al. C-reactive protein makes human endothelium stiff and tight. Hypertension. 2011;57(2):231–7.PubMed
61.
Carrero JJ, Fonollá J, Marti JL, Jiménez J, Boza JJ, López-Huertas E. Intake of fish oil, oleic acid, folic acid, and vitamins B-6 and E for 1 year decreases plasma C-reactive protein and reduces coronary heart disease risk factors in male patients in a cardiac rehabilitation program. J Nutr. 2007;137(2):384–90.PubMed
62.
Ala OA, Akintunde AA, Ikem RT, Kolawole BA, Ala OO, Adedeji T. Association between insulin resistance and total plasma homocysteine levels in type 2 diabetes mellitus patients in south West Nigeria. Diabetes Metab Syndr. 2017;11:S803–S9.PubMed
63.
Tripathi M, Zhang CW, Singh BK, Sinha RA, Moe KT, DeSilva DA, et al. Hyperhomocysteinemia causes ER stress and impaired autophagy that is reversed by vitamin B supplementation. Cell Death Dis. 2016;7(12):e2513.PubMedPubMedCentral
64.
Shpilberg Y, Beaudry JL, D’Souza A, Campbell JE, Peckett A, Riddell MC. A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis Model Mech. 2012;5(5):671–80.PubMed
65.
Verhoeven F, Prati C, Maguin-Gaté K, Wendling D, Demougeot C. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):258.PubMedPubMedCentral
66.
Bodnaruc AM, Prud’homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab. 2016;13(1):92.
67.
Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403.PubMed
68.
Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol. 2018;9:672.
69.
An FM, Chen S, Xu Z, Yin L, Wang Y, Liu AR, et al. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: studies in vivo and in vitro. Neuroscience. 2015;300:75–84.PubMed
70.
71.
Zhang LW, Tobin GAM, Rouse RL. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line. Toxicol Appl Pharmacol. 2012;264(2):274–83.PubMed
72.
Iakoubov R, Ahmed A, Lauffer LM, Bazinet RP, Brubaker PL. Essential role for protein kinase Czeta in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology. 2011;152(4):1244–52.PubMed
73.
Khound R, Taher J, Baker C, Adeli K, Su Q. GLP-1 elicits an intrinsic gut–liver metabolic signal to ameliorate diet-induced VLDL overproduction and insulin resistance. Arterioscler Thromb Vasc Biol. 2017;37(12):2252–9.PubMed
74.
75.
Morton GJ, Schwartz MW. Leptin and the central nervous system control of glucose metabolism. Physiol Rev. 2011;91(2):389–411.PubMedPubMedCentral
76.
Wang T-N, Chang W-T, Chiu Y-W, Lee C-Y, Lin K-D, Cheng YY, et al. Relationships between changes in leptin and insulin resistance levels in obese individuals following weight loss. Kaohsiung J Med Sci. 2013;29(8):436–43.PubMed
77.
Blanquer-Rossello MM, Santandreu FM, Oliver J, Roca P, Valle A. Leptin modulates mitochondrial function, dynamics and biogenesis in MCF-7 cells. J Cell Biochem. 2015;116(9):2039–48.PubMed
78.
Paz-Filho G, Mastronardi C, Wong M-L, Licinio J. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 2012;16(Suppl 3):S549–55.PubMedPubMedCentral
79.
Dong H-Y, Xu M, Ji Z-Y, Wang Y-X, Dong M-Q, Liu M-L, et al. Leptin attenuates lipopolysaccharide or oleic acid-induced acute lung injury in mice. Am J Respir Cell Mol Biol. 2013;49(6):1057–63.PubMed
80.
81.
Cai D. One step from prediabetes to diabetes: hypothalamic inflammation? Oxford: Oxford University Press; 2012.
82.
Siva ZO, Uluduz D, Keskin FE, Erenler F, Balci H, Uygunoglu U, et al. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine. Cephalalgia. 2018;38(11):1773–81.PubMed
83.
Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes. 2002;51(2):271–5.PubMed
84.
Luo G, Xu X, Guo W, Luo C, Wang H, Meng X, et al. Neuropeptide Y damages the integrity of mitochondrial structure and disrupts energy metabolism in cultured neonatal rat cardiomyocytes. Peptides. 2015;71:162–9.PubMed
85.
Jin S, Diano S. Mitochondrial dynamics and hypothalamic regulation of metabolism. Endocrinology. 2018;159(10):3596–604.PubMedPubMedCentral
86.
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4:37.
87.
88.
Perdomo L, Beneit N, Otero YF, Escribano Ó, Díaz-Castroverde S, Gómez-Hernández A, et al. Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process. Cardiovasc Diabetol. 2015;14(1):75.PubMedPubMedCentral
89.
Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011;51(5):993–9.PubMed
90.
Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69.PubMedPubMedCentral
91.
Victor VM, Rocha M, Herance R, Hernandez-Mijares A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des. 2011;17(36):3947–58.PubMed
92.
Nakbi A, Tayeb W, Dabbou S, Issaoui M, Grissa AK, Attia N, et al. Dietary olive oil effect on antioxidant status and fatty acid profile in the erythrocyte of 2, 4-D-exposed rats. Lipids Health Dis. 2010;9(1):89.PubMedPubMedCentral
93.
Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114(3):525–31.PubMed
94.
Karakaya P, Ozdemir B, Mert M, Okuturlar Y. Relation of Paraoxonase 1 activity with biochemical variables, brachial artery intima-media thickness in patients with diabetes with or without obesity. Obes Facts. 2018;11(1):56–66.PubMedPubMedCentral
95.
Jornayvaz FR, Brulhart-Meynet M-C, James RW. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2009;19(9):613–9.PubMed
96.
Palomer X, Pizarro-Delgado J, Barroso E, Vázquez-Carrera M. Palmitic and oleic acid: the yin and yang of fatty acids in type 2 diabetes mellitus. Trends Endocrinol Metab. 2018;29(3):178–90.PubMed
97.
Chen K. Athero-protective actions of two oral antidiabetic drugs: suppression of inflammation and oxidative stress. J Cardiovasc Dis Res. 2012;3(1):3–4.PubMedPubMedCentral
98.
Ma L, Guo X, Chen W. Inhibitory effects of oleoylethanolamide (OEA) on H(2)O(2)-induced human umbilical vein endothelial cell (HUVEC) injury and apolipoprotein E knockout (ApoE−/−) atherosclerotic mice. Int J Clin Exp Pathol. 2015;8(6):6301–11.PubMedPubMedCentral
99.
Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81.PubMedPubMedCentral
100.
Dhayal S, Morgan NG. The significance of GPR119 agonists as a future treatment for type 2 diabetes. Drug News Perspect. 2010;23(7):418–24.PubMed
101.
Liu J, Wu X, Franklin JL, Messina JL, Hill HS, Moellering DR, et al. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab. 2009;298(3):E565–E76.PubMedPubMedCentral
102.
Guo L, Guo ZX, Gong HP, Shang YY, Zhong M, Zhang Y, et al. Tribbles homolog 3 is induced by high glucose and associated with apoptosis in human endothelial cells. Mol Med Rep. 2015;12(2):1963–70.PubMed
103.
Geng T, Hu W, Broadwater M, Snider J, Bielawski J, Russo S, et al. Fatty acids differentially regulate insulin resistance through endoplasm reticulum stress-mediated induction of tribbles homologue 3: a potential link between dietary fat composition and the pathophysiological outcomes of obesity. Diabetologia. 2013;56(9):2078–87.PubMed
104.
Sun X, Bao B, Gao X, Yan D, Zhou Y. Effect of glycated hemoglobin on heart function of the patients with revascularization of coronary artery. Int J Clin Exp Pathol. 2015;8(6):7181–8.PubMedPubMedCentral
105.
Ye S, Ruan P, Yong J, Shen H, Liao Z, Dong X. The impact of the HbA1c level of type 2 diabetics on the structure of haemoglobin. Sci Rep. 2016;6:33352.PubMedPubMedCentral
106.
Moreno B, de Faria AP, Ritter AMV, Yugar LBT, Ferreira-Melo SE, Amorim R, et al. Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus. J Clin Hypertens (Greenwich). 2018;20(5):910–7.
107.
Silva FP, Carla IA, Marcelino G, Maiara LCC, de Cássia FK, de Cássia AGR, et al. Fatty acids consumption: the role metabolic aspects involved in obesity and its associated disorders. Nutrients. 2017;9(10):1158.
108.
Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87(3):497–9.PubMed
109.
Eirin A, Lerman A, Lerman LO. Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. Eur Heart J. 2014;35(46):3258–66.PubMedPubMedCentral
110.
Terés S, Barceló-Coblijn G, Benet M, Alvarez R, Bressani R, Halver J, et al. Oleic acid content is responsible for the reduction in blood pressure induced by olive oil. Proc Natl Acad Sci U S A. 2008;105(37):13811–6.PubMedPubMedCentral
Metadata
Title
Current perspectives of oleic acid: Regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes
Authors
Kanwal Rehman
Kamran Haider
Komal Jabeen
Muhammad Sajid Hamid Akash
Publication date
01-12-2020
Publisher
Springer US
Keywords
Insulins
Insulins
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2020
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09549-6

Other articles of this Issue 4/2020

Reviews in Endocrine and Metabolic Disorders 4/2020 Go to the issue

ReviewPaper

Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis

ReviewPaper

Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases

ReviewPaper

Review of the veteran affairs diabetes trial: Lessons learned

ReviewPaper

Acromegaly, inflammation and cardiovascular disease: a review

ReviewPaper

Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management

ReviewPaper

Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits